(NP (NP-COOD (NP (VBN Chlorinated) (NP-COOD (NP (NNS dibenzo-p-dioxins)) (CC and) (NP (NNS dibenzofurans)))) (CC and) (NP (DT the) (JJ human) (JJ immune) (NN system))) (. .))
(NP (LST (LS 1) (. .)) (NP (NN Blood) (NN cell) (NNS receptors)) (PP (IN in) (NP (NP (NNS volunteers)) (PP (IN with) (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens))))) (. .))
(S (S (NP-SBJ (-NONE- *-51)) (VP (VBG Using) (NP-COOD (NP (NP (JJ monoclonal) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (NNS mAbs)) (-RRB- -RRB-))) (CC and) (NP (NN flow) (NN cytometry))))) (, ,) (NP-SBJ-51 (PRP we)) (VP (VBD studied) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN surface) (NNS receptors)))) (PP (IN on) (NP (NP (NN lymphocyte) (NNS subpopulations)) (PP (IN of) (NP (NP (NNS workers)) (PP (IN with) (NP (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens)) (PP-COOD (PP (IN of) (NP (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (JJ other) (NP (NP (VBN polychlorinated) (NP-COOD (NP (NNS dibenzo-p-dioxins)) (CC and) (NP (NNS dibenzofurans)))) (PRN (-LRB- -LRB-) (NP (NN (PCDF PCDD))) (-RRB- -RRB-)))))) (, ,) (VP (VBN expressed) (NP (-NONE- *)) (ADVP (RB here)) (PP (IN as) (NP (NP (NN International-Toxicity) (NN Equivalencies)) (PRN (-LRB- -LRB-) (NP (NN I-TE)) (-RRB- -RRB-)))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN hypothesis)) (SBAR (WHNP-52 (-NONE- 0)) (S (NP-SBJ-53 (-NONE- *T*-52)) (VP (TO to) (VP (VB be) (VP (VBN tested) (NP (-NONE- *-53)))))))) (VP (VBD was) (SBAR-PRD (IN whether) (CC or) (RB not) (S (NP-SBJ (NNS humans)) (VP (VBP exhibit) (NP (NP (DT a) (JJ similar) (NN susceptibility)) (PP (TO to) (NP (NNS (PCDFs PCDDs))))) (PP (IN with) (NN respect) (TO to) (NP (NP (DT the) (NN surface) (NNS receptors)) (VP (VBN found) (ADVP-TMP (RB previously)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (JJ small) (NNS doses)) (PP (IN of) (NP (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-)))) (PP (IN in) (NP (FW Callithrix) (FW jacchus))))))))))))))) (. .))
(S (NP-SBJ (DT These)) (VP (VBP are) (: :) (NP-PRD-COOD (NP (NP (NP (NP (JJ helper-inducer)) (PRN (-LRB- -LRB-) (NP (NN memory)) (-RRB- -RRB-))) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ CD4+CD45R0+CD45RA-CD29highCD11a+)) (-RRB- -RRB-))) (, ,) (NP (JJ CD20+) (NN B) (NNS cells)) (, ,) (CC and) (NP (NP (JJ cytotoxic) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ (CD57+ CD8+CD56+))) (-RRB- -RRB-))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-55 (NP (CD 68) (NNS triple-labellings)) (PP (IN with) (NP (NNS mAbs)))) (VP (VBD were) (VP (VBN performed) (NP (-NONE- *-55)) (PP (IN on) (NP (NP (DT the) (NNS cells)) (PP (IN of) (NP (DT each) (NN volunteer))))) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (ADVP (RB possibly)) (VB generate) (NP (JJ further) (NNS hypotheses))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN evaluated) (SBAR (IN whether) (S (NP-SBJ-56 (NP (DT any)) (PP (IN of) (NP (DT the) (NNS variables)))) (VP (MD might) (VP (VB be) (VP (VBN used) (NP (-NONE- *-56)) (PP (IN as) (NP (NP (DT a) (NN biomarker)) (PP (IN of) (NP (NNS effects))) (PP (IN for) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NNS compounds)))))))))))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD were) (NP-PRD (NP (CD two) (JJ main) (NNS goals)) (: :) (S-COOD (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP-SBJ (NP (NNS workers)) (PP (IN with) (NP (NP (DT a) (ADJP (RB moderately) (VBN increased)) (NN (PCDF-body PCDD)) (NN burden)) (PRN (-LRB- -LCB-) (NP (NP-COOD (NP (ADJP (QP (CD 25-140)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 104-522)) (NN ppt)) (NN I-TE))) (PP (IN in) (NP (NN blood) (NN fat)))) (-RRB- -RCB-))))) (VP (VBP exhibit) (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN surface) (NNS receptors)) (PP (IN of) (NP (JJ white) (NN blood) (NNS cells))))) (, ,) (SBAR (IN as) (S (NP-SBJ-57 (-NONE- *)) (VP (VBN observed) (NP (-NONE- *-57)) (PP (IN in) (NP (NP (JJ previous) (NNS studies)) (PP (IN in) (NP (JJ non-human) (NNS primates)))))))))))))) (, ,) (CC and) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB clarify) (SBAR (IN whether) (S (NP-SBJ-102 (NP (NNS persons)) (PP (IN at) (NP (NP (NP (DT the) (JJ upper) (NN range)) (PRN (-LRB- -LCB-) (NP (NP-COOD (NP (ADJP (QP (CD 10-23)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 30-90)) (NN ppt)) (NN I-TE))) (PP (IN in) (NP (NN blood) (NN fat)))) (-RRB- -RCB-))) (PP (IN of) (NP (DT the) (NN body) (NN burden) (NN reference) (NNS values))) (PP (IN of) (NP (DT a) (ADJP (ADVP (RB not) (RB particularly)) (VBN exposed)) (NN population)))))) (VP (VBP show) (NP (JJ detectable) (NNS deviations)) (PP (IN in) (NP (DT these) (JJ immunological) (NNS variables))) (, ,) (SBAR-TMP (WHADVP-58 (WRB when)) (S (NP-SBJ-103 (-NONE- *-102)) (VP (VBN compared) (NP (-NONE- *-103)) (PP (IN with) (NP (NP (NNS persons)) (PP (IN at) (NP (NP (NP (DT the) (ADJP-COOD (ADJP (JJR lower)) (CC and) (ADJP (NN medium))) (NN range)) (PRN (-LRB- -LCB-) (NP-COOD (NP (ADJP (QP (CD 1-3)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 9-29)) (NN ppt)) (NN I-TE))) (-RRB- -RCB-))) (PP (IN of) (NP (DT these) (NN body) (NN burden) (NN reference) (NNS values))))))) (ADVP (-NONE- *T*-58)))))))))))))) (. .))
(S (NP-SBJ (NP (NN Regression) (NN analysis)) (PP (IN of) (NP (PRP$ our) (NNS data)))) (VP (VBD revealed) (NP (NP (JJ slight) (NNS trends)) (PP (IN for) (NP (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS biomarkers)))) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (JJ CD45R0+)) (-RRB- -RRB-)))))) (. .))
(S (PP (IN With) (NP (CD one) (NN exception))) (, ,) (NP-SBJ (DT these)) (VP (VBD were) (ADVP (DT all)) (NP-PRD (NNS increases))) (. .))
(S (NP-SBJ (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS alterations)) (VP (VBN observed) (NP (-NONE- *)))))) (VP (VBP are) (PP-PRD (IN of) (NP (JJ medical) (NN relevance)))) (. .))
(S (NP-SBJ (NP (DT The) (JJ slight) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (JJ CD4+CD45R0+) (NNS cells)))))) (VP (VBD remained) (ADJP-PRD (JJ significant)) (PP-TMP (RB even) (IN after) (NP (NP (JJ covariant) (NN analysis)) (VP (VBG taking) (NP (JJ age-related) (NNS changes)) (PP (IN into) (NP (NN account))))))) (. .))
(S (ADVP (RB Altogether)) (, ,) (NP-SBJ (DT the) (NNS data)) (VP (VBP do) (RB not) (VP (VB provide) (NP (NP (DT any) (NN evidence)) (SBAR (WHNP-59 (-NONE- 0)) (S (NP-SBJ (-NONE- *T*-59)) (VP (TO to) (VP (VB support) (NP (DT an) (NN assumption) (SBAR (IN that) (S (NP-SBJ (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens)) (PP (IN of) (NP (NNS (PCDFs PCDDs)))) (PP (IN in) (NP (NNS adults)))) (VP (VBP induce) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ cellular) (NNS components)) (PP (IN of) (NP (DT the) (JJ human) (JJ immune) (NN system))))))))))))))))) (. .))
(S (NP-SBJ (JJ Adult) (NNS humans)) (ADVP (RB certainly)) (VP (VBP are) (ADJP-PRD (ADJP (RBR less) (JJ susceptible) (PP (TO to) (NP (NP (DT this) (NN action)) (PP (IN of) (NP (NNS (PCDFs PCDDs))))))) (PP (IN than) (NP (JJ adolescent) (FW Callithrix) (FW jacchus))))) (. .))
